Concert Pharmaceuticals Inc (CNCE) has fallen Monday morning, with the stock declining -4.09% in pre-market trading to 3.52. CNCE's short-term technical score of 3 indicates that the stock has traded less bullishly over the last month than 97% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, Concert Pharmaceuticals Inc ranks higher than 8% of stocks. Concert Pharmaceuticals Inc has risen 22.74% over the past month, closing at $2.91 on October 11. During this period of time, the stock fell as low as $2.69 and as high as $4.49. CNCE has an average analyst recommendation of Strong Buy. The company has an average price target of $17.00.
CNCE has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on CNCE!